3 Reasons It's Not Too Late to Buy Eli Lilly Stock

Eli Lilly reported Q1 revenue of $19.8 billion, up 56% year over year, with adjusted EPS of $8.55, up 156%, driven by strong GLP-1 sales: Mounjaro rose 125% to $8.7 billion and Zepbound reached $4.2 billion. The company also gained a new growth driver with FDA approval of the oral GLP-1 drug Foundayo, while a proposed FDA change could further limit compounded tirzepatide competition. Non-GLP-1 products are also gaining traction, with Jaypirca up 79% to $165 million and several other drugs more than doubling.

Analysis

The bigger takeaway is that Lilly is transitioning from a single-product growth story into a platform business with multiple shots on goal. That matters because it lowers the probability that GLP-1 normalization ever fully derates the multiple: even if obesity pricing compresses, the company can still compound off adjacent launches and a deeper pipeline. In other words, the market is no longer just underwriting peak Mounjaro/Zepbound demand; it is buying a durable R&D-and-commercialization machine with unusually strong execution leverage.

The regulatory angle is more powerful than the headline suggests. If compounding access tightens, the immediate beneficiaries are not just branded volumes but also list-price discipline across the category, because discount channels tend to anchor patient and payer expectations. The second-order effect is that weaker competitors and telehealth middlemen lose the ability to undercut at scale, which should improve refill persistence and reduce promotional intensity over the next few quarters.

The key risk is not demand fatigue in the next month; it is a slower, more incremental erosion in 2025-26 from payer step-edits, formulary restrictions, and eventual class-wide price normalization as rivals scale capacity. The market may also be underestimating how much of the current growth is being pulled forward by new-patient conversion from non-injectable access points, which can overstate steady-state elasticity. If obesity adoption broadens faster than payers can restrict, the stock can still work, but the easier money is likely in the next 3-6 months rather than on a multi-year straight-line extrapolation.

Key Decisions for Investors

• Stay long LLY into the next 1-2 quarters; the asymmetry is still favorable because regulatory tightening can lift near-term revenue quality faster than consensus can haircut it. Best risk/reward is on pullbacks after strength, not chasing upside spikes.
• Use call spreads rather than outright equity for a 3-6 month expression in LLY; the catalyst stack is strong, but valuation leaves less room for multiple expansion than for earnings beats. Favor upside structures that monetize the next two earnings prints.
• Pair long LLY vs short a basket of GLP-1 adjacencies/telehealth distributors exposed to compounding and price transparency. The thesis is that branded insulin-and-obesity leaders capture share as the gray market loses operating leverage over the next 6-12 months.
• Avoid over-committing to the long at current multiples without a regulatory confirmation point; if the FDA action stalls, the stock could de-rate 5-10% on loss of near-term pricing power before fundamentals reassert.